Is to develop pan-influenza inhibitors targeting the PA endonuclease from the viral replication complex by demonstrating pyronaridine as a viable single dose treatment for ebola infection in non-human…
Active Definitive Contract Awarded Last action
- Contract number
- 75N93025C00039
- Awardee
-
Collaborations Pharmaceuticals, Inc. UEI EFJCLL37KKH3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,999,195
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20251 · Posted Jul 18, 2024
- Contract value 100% obligated
- $1,999,195.12 Current and potential, with all options
- Completion date 84% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 4 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Raleigh, NC 27606, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $0 | |
| Original award | $1,999,195 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $1,999,195.12 definitive contract to Collaborations Pharmaceuticals, Inc., a small business, for development of pan-influenza inhibitors targeting the PA endonuclease from the viral replication complex on September 29, 2025, under a total small business set-aside.
The work involves demonstrating pyronaridine as a viable single-dose treatment for Ebola infection in non-human primates to justify further in vivo studies. This is a Small Business Innovation Research Phase II project. Place of performance is Raleigh, NC. The contract carries firm fixed price terms with an ultimate completion date of December 29, 2026.
Description
Is to develop pan-influenza inhibitors targeting the PA endonuclease from the viral replication complex by demonstrating pyronaridine as a viable single dose treatment for ebola infection in non-human primates to justify further in vivo studies for u
Quick answers
Who was awarded contract 75N93025C00039?
75N93025C00039 was awarded to Collaborations Pharmaceuticals, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 29, 2025.
How much is contract 75N93025C00039 worth?
The government has obligated $1,999,195 on 75N93025C00039.
Was contract 75N93025C00039 competed?
The extent of competition for 75N93025C00039 was full and open competition after exclusion of sources. The government received 4 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award